BR112021016762A2 - Cocristal de selinexor, composição farmacêutica, método de tratamento de doenças, e, processo para a preparação de cocristal de selinexor - Google Patents

Cocristal de selinexor, composição farmacêutica, método de tratamento de doenças, e, processo para a preparação de cocristal de selinexor Download PDF

Info

Publication number
BR112021016762A2
BR112021016762A2 BR112021016762-5A BR112021016762A BR112021016762A2 BR 112021016762 A2 BR112021016762 A2 BR 112021016762A2 BR 112021016762 A BR112021016762 A BR 112021016762A BR 112021016762 A2 BR112021016762 A2 BR 112021016762A2
Authority
BR
Brazil
Prior art keywords
selinexor
succinic acid
cocrystal
vanillin
process according
Prior art date
Application number
BR112021016762-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Clifton Hamilton
Original Assignee
Johnson Matthey Public Limited Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson Matthey Public Limited Company filed Critical Johnson Matthey Public Limited Company
Publication of BR112021016762A2 publication Critical patent/BR112021016762A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • C07C47/58—Vanillin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112021016762-5A 2019-03-20 2020-03-19 Cocristal de selinexor, composição farmacêutica, método de tratamento de doenças, e, processo para a preparação de cocristal de selinexor BR112021016762A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962821203P 2019-03-20 2019-03-20
US62/821,203 2019-03-20
PCT/US2020/023530 WO2020191140A1 (en) 2019-03-20 2020-03-19 Co-crystal forms of selinexor

Publications (1)

Publication Number Publication Date
BR112021016762A2 true BR112021016762A2 (pt) 2021-10-19

Family

ID=70293085

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021016762-5A BR112021016762A2 (pt) 2019-03-20 2020-03-19 Cocristal de selinexor, composição farmacêutica, método de tratamento de doenças, e, processo para a preparação de cocristal de selinexor

Country Status (8)

Country Link
US (1) US12559478B2 (https=)
EP (1) EP3941588A1 (https=)
JP (2) JP2022524741A (https=)
KR (1) KR20210141936A (https=)
CN (1) CN113423468A (https=)
BR (1) BR112021016762A2 (https=)
CA (1) CA3130107A1 (https=)
WO (1) WO2020191140A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021016762A2 (pt) 2019-03-20 2021-10-19 Johnson Matthey Public Limited Company Cocristal de selinexor, composição farmacêutica, método de tratamento de doenças, e, processo para a preparação de cocristal de selinexor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104230936A (zh) * 2009-12-03 2014-12-24 阿斯利康(瑞典)有限公司 三唑并[4,5-d]嘧啶血小板聚集抑制剂的共晶体
EP4234545A3 (en) 2011-07-29 2023-09-06 Karyopharm Therapeutics Inc. Hydrazide containing nuclear transport modulators and uses thereof
US9808450B2 (en) * 2013-03-26 2017-11-07 Celgene Corporation Solid forms comprising 3-(4-amino-1-OXO-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
US20180230140A1 (en) * 2014-06-30 2018-08-16 Basf Se Multicomponent crystals of dasatinib with menthol or vanillin
KR102608259B1 (ko) 2014-08-15 2023-11-29 카리오팜 쎄라퓨틱스, 인코포레이티드 셀리넥소의 다형태
WO2017118940A1 (en) * 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
EP3565813A1 (en) * 2017-01-05 2019-11-13 Watson Laboratories, Inc. Novel crystalline forms of selinexor and process for their preparation
CN107089946B (zh) * 2017-05-05 2020-04-03 浙江科技学院 一种诺氟沙星与香兰素共晶及其制备方法
BR112021016762A2 (pt) 2019-03-20 2021-10-19 Johnson Matthey Public Limited Company Cocristal de selinexor, composição farmacêutica, método de tratamento de doenças, e, processo para a preparação de cocristal de selinexor

Also Published As

Publication number Publication date
US20210395232A1 (en) 2021-12-23
CA3130107A1 (en) 2020-09-24
KR20210141936A (ko) 2021-11-23
JP2025134935A (ja) 2025-09-17
JP2022524741A (ja) 2022-05-10
CN113423468A (zh) 2021-09-21
EP3941588A1 (en) 2022-01-26
US12559478B2 (en) 2026-02-24
WO2020191140A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
CN102791719B (zh) 二胺衍生物的晶体及其制备方法
CN109153656B (zh) 他发米帝司葡甲胺盐的晶型e及其制备方法和用途
JP2022000451A (ja) ピリジノイルピペリジン５−ｈｔ１ｆアゴニストに関する組成物および方法
BR122023022641A2 (pt) Forma cristalina de monoidrato, composição farmacêutica compreendendo a mesma, método de inibição da atividade de pde9 em um paciente e processo para preparar a forma de monoidrato 2
JP2025134935A (ja) セリネクソールの共結晶形態
CN111278808B (zh) 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式
CA2932560C (en) Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine pharmaceutically acceptable salts and uses thereof
BR112014025586B1 (pt) Forma cristalina de (s)-4-amino-n-(1-(4-clorofenil)-3-hidroxipropil)-1-(7h-pirrolo[2,3-d] pirimidin4-il)piperidina-4-carboxamida, composições farmacêuticas compreendendo a mesma, seu uso e comprimido farmacêutico compreendendo a mesma
BR112020017807A2 (pt) Composto, e, processos para a preparação da forma i em estado sólido de solvato de abc em metanol variável, para a preparação da forma iii de hidrato e abemaciclib em estado sólido e para a preparação da forma ii de abemaciclib anidro em estado sólido
BR112020021394A2 (pt) as formas cristalinas de um composto
KR102858471B1 (ko) Lta4h 저해제의 결정질 형태
EA039764B1 (ru) Соль n-(2,6-диэтилфенил)-8-({4-[4-(диметиламино)пиперидин-1-ил]-2-метоксифенил}амино)-1-метил-4,5-дигидро-1h-пиразоло[4,3-h]хиназолин-3-карбоксамида, ее получение и препараты, которые ее содержат
JP2022540466A (ja) 非晶質ウムブラリシブモノトシレート
JP2018510173A (ja) トピロキソスタットの新規結晶形及びその製造方法
US20210094961A1 (en) Form of ponatinib
KR101285050B1 (ko) 결정형 1Ｈ-이미다조[4,5-ｂ]피리딘-5-아민,7-[5-[(시클로헥실메틸아미노)-메틸]-1Ｈ-인돌-2-일]-2-메틸, 설페이트 (1:1), 삼수화물 및 이의 약학적 용도
JP2014051470A (ja) スルホニルアミジン化合物の結晶
US20250339436A1 (en) Crystalline forms of mrtx1133
RU2808992C2 (ru) Кристаллические формы ингибитора lta4h
JP2025186242A (ja) ６－クロロ－７－（４－（４－クロロベンジル）ピペラジン－１－イル）－２－（１，３－ジメチル－１Ｈ－ピラゾール－４－イル）－３Ｈ－イミダゾ［４，５－ｂ］ピリジンの塩及び多形体
HK40076742A (en) Novel salt of terphenyl compound
BR112021022335B1 (pt) Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin4-il)-4- metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf, seus usos, e composição farmacêutica
BR112020003617B1 (pt) Sais de um composto e as formas cristalinas dos mesmos
BR112019023592A2 (pt) Formas cristalinas de seletalisibe
JP2020513006A (ja) アファチニブジマレアートの新規形態

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]